Category Archives: AZBio News

New Online Resource Spotlights Life Science Investments in Arizona and Across the U.S.

Posted on by

We Work For Health is tracking every new U.S. biopharma facility announcement and news report, revealing more than $425 billion being invested to drive new R&D, expand manufacturing and create jobs nationwide. The continually updated database is accessible below through a state map of announcements that mention specific cities or states and also a tracker of every public commitment since January 2025.Continue reading→

NuvOx and FYR Bio Announce NCI Funding for Liquid Biopsy Collaboration Supporting NuvOx’s Phase IIb Glioblastoma Trial

Posted on by

Tucson, AZ – September 26, 2025 – NuvOx Therapeutics, Inc. (“NuvOx”) and FYR Bio (“FYR”) today announced a collaboration pairing NuvOx’s Phase IIb glioblastoma trial of NanO₂ with FYR’s EV-based liquid-biopsy expertise to provide additional biomarker insights that support clinical development, through an NCI (a division of NIH) grant “Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic”.Continue reading→

CND Life Sciences is Granted FDA Breakthrough Device Designation for Its Skin Biopsy-Based Syn-One Test®

Posted on by

SCOTTSDALE, AZ, October 7, 2025 – CND Life Sciences, Inc. (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for the company’s Syn-One Test® for aiding the diagnosis of synucleinopathies in patients aged 40 years and older with neurologic conditions that present with clinical features suggestive of a synucleinopathy.

Continue reading→

The Journey of a Plasma Donation

Posted on by

Plasma Donors hold the missing puzzle piece for those who rely on plasma-derived therapies.

October is Plasma Awareness Month, an opportunity for CSL to raise awareness about the importance and need for plasma donations to manufacture life-saving therapies.Continue reading→

Amgen Makes Repatha® Available Through AMGENNOW, A Direct-to-Patient Program in the U.S.

Posted on by

Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price 

THOUSAND OAKS, Calif. Oct. 6, 2025 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial.Continue reading→

FDA Announces New ANDA Prioritization Pilot to Support U.S. Generic Drug Manufacturing and Testing

Posted on by

[10/3/2025] Today, the U.S. Food and Drug Administration (FDA) is announcing a new pilot prioritization program for the review of abbreviated new drug applications (ANDAs) (ANDAs) that aims to spur and reward investment in U.S. drug manufacturing and research and development and strengthen the domestic pharmaceutical supply chain by providing faster reviews for generic companies who test and manufacture their products in the U.S.Continue reading→